The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Key unmet needs in the treatment of immune-mediated TTP
Júlia Weisinger, MD, Hospital Saint-Antoine AP-HP, Paris, France, addresses the unmet needs in treating immune-mediated thrombotic thrombocytopenic purpura (TTP). She emphasizes the need for more data in the preemptive setting to determine which patients require treatment and the most effective drugs for them. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
